KARYOTYPE
SUSANA BAENA GARCIA
TEACHER: LINA MARTINEZ
MOLECULAR BIOLOGY
INTRODUCTION
Karyotype is the chromosome
constitution of an individual.
 
NIPT, which analyzes cell-free fetal
DNA circulating in maternal blood,
is a new option in the prenatal
screening and testing
paradigm for trisomy 21 and a
few other fetal chromosomal
aneuploidies.
CERTAIN ABNORMAL PRENATAL TESTING
RESULTS AND SUBSEQUENT DIAGNOSIS OF
MATERNAL CANCER
A small number of occult malignancies were subsequently
diagnosed among pregnant women whose noninvasive prenatal
testing results showed chromosomal abnormalities but the fetal
karyotype was subsequently shown to be normal
CERTAIN ABNORMAL PRENATAL TESTING
RESULTS AND SUBSEQUENT DIAGNOSIS OF
MATERNAL CANCER
CERTAIN ABNORMAL PRENATAL TESTING
RESULTS AND SUBSEQUENT DIAGNOSIS OF
MATERNAL CANCER
CERTAIN ABNORMAL PRENATAL TESTING
RESULTS AND SUBSEQUENT DIAGNOSIS OF
MATERNAL CANCER
STUDENT OBSERVATION
I think this study is the first of many that
can result from this to study in a non
-invasive way the mother and the baby and
in the future to find solutions to these
issues
SEQUENOMLABORATORIES ANNOUNCES
LAUNCHOF MATERNIT GENOME TEST
• This test is the first noninvasive prenatal test (NIPT) to provide
karyotype-level insight into fetal chromosomal status prior to
considering an invasive procedure.
• The MaterniT GENOME test adds genome-wide identification of
chromosomal gains or losses greater than 7 megabases (Mb)
that were previously undetectable by NIPT."
SEQUENOM LABORATORIES ANNOUNCES
LAUNCH OF MATERNIT GENOME TEST
• While cell-free DNA: significant improvement in identifying
pregnancies at riskforaneuploidies
• There remain a numberof significant cytogenetic abnormalities that
noninvasive prenatal testing has not been able to identify
SEQUENOM LABORATORIES ANNOUNCES
LAUNCH OF MATERNIT GENOME TEST
• Was recently highlighted in an article by Hume JH, et al, published in the
peer-reviewed journal PrenatalDiagnosis.
• MaterniT GENOME test will be presented at the 19th
 International
Conference on Prenatal Diagnosis and Treatment
• The MaterniT GENOME test will be available to physicians laterthis
quarter.
SEQUENOMLABORATORIES ANNOUNCES
LAUNCHOF MATERNIT GENOME TEST
President and Chief Executive Officerof
Sequenom.
•"As pioneers and innovators in noninvasive
prenatal testing, we believe MaterniT
GENOME represents a safe, cost effective
and meaningful breakthrough in NIPT,
supporting physicians in providing superior
prenatal care fortheirpatients."
STUDENT OBSERVATION
•I think this new release will be a positive thing
because it is a safe way to study the baby
before birth and find defects in their genome
and thus find a way to improve their
development
MEDICAL UTILITY
These studies have great
medical importance as both
seek less invasive possible
way to find anomalies in the
fetus.
MEDICAL UTILITY
•The first news opens a new field of research
into changes in the mother's pregnancy and
her child 's genome .
MEDICAL UTILITY
•And the second increased the most reliable
diagnostic findings and the baby before birth
MEDICAL UTILITY
Both studies will be useful to find treatments
to Improve Quality of Life to the baby and
the mother
BIBLIOGRAFIA
Secuenom,inc (July 13, 2015). Certain abnormal prenatal testing results and
subsequent diagnosis of maternal cancer. New Medical. Retrieved July 19,2015
from
www.news-medical.net/news/20150713/Sequenom-Laboratories-announces-launch-of-MaterniT
 
The JAMA Network Journals(July 13, 2015). Certain abnormal prenatal testing
results and subsequent diagnosis of maternal cancer. Retievered July 19,2015 from
www.sciencedaily.com/releases/2015/07/150713172229.htm
 
MARTINEZ SÁNCHEZ, Lina María. Biología molecular. 2. ed. Medellín: UPB. Fac.
de Medicina, 2006. 208 p.
 
NCHPEG, The Jakson Laboratory.Non-Invasive Prenatal Testing Factsheet.
Retrivered july 26, 2015 from www.nchpeg.org/index.php?
option=com_content&view=article&id=384&Itemid=255
 
 
G
R
A
C
I
A
S

Karyotype

  • 1.
    KARYOTYPE SUSANA BAENA GARCIA TEACHER:LINA MARTINEZ MOLECULAR BIOLOGY
  • 4.
    INTRODUCTION Karyotype is thechromosome constitution of an individual.   NIPT, which analyzes cell-free fetal DNA circulating in maternal blood, is a new option in the prenatal screening and testing paradigm for trisomy 21 and a few other fetal chromosomal aneuploidies.
  • 5.
    CERTAIN ABNORMAL PRENATALTESTING RESULTS AND SUBSEQUENT DIAGNOSIS OF MATERNAL CANCER A small number of occult malignancies were subsequently diagnosed among pregnant women whose noninvasive prenatal testing results showed chromosomal abnormalities but the fetal karyotype was subsequently shown to be normal
  • 6.
    CERTAIN ABNORMAL PRENATALTESTING RESULTS AND SUBSEQUENT DIAGNOSIS OF MATERNAL CANCER
  • 7.
    CERTAIN ABNORMAL PRENATALTESTING RESULTS AND SUBSEQUENT DIAGNOSIS OF MATERNAL CANCER
  • 8.
    CERTAIN ABNORMAL PRENATALTESTING RESULTS AND SUBSEQUENT DIAGNOSIS OF MATERNAL CANCER
  • 9.
    STUDENT OBSERVATION I thinkthis study is the first of many that can result from this to study in a non -invasive way the mother and the baby and in the future to find solutions to these issues
  • 10.
    SEQUENOMLABORATORIES ANNOUNCES LAUNCHOF MATERNITGENOME TEST • This test is the first noninvasive prenatal test (NIPT) to provide karyotype-level insight into fetal chromosomal status prior to considering an invasive procedure. • The MaterniT GENOME test adds genome-wide identification of chromosomal gains or losses greater than 7 megabases (Mb) that were previously undetectable by NIPT."
  • 11.
    SEQUENOM LABORATORIES ANNOUNCES LAUNCHOF MATERNIT GENOME TEST • While cell-free DNA: significant improvement in identifying pregnancies at riskforaneuploidies • There remain a numberof significant cytogenetic abnormalities that noninvasive prenatal testing has not been able to identify
  • 12.
    SEQUENOM LABORATORIES ANNOUNCES LAUNCHOF MATERNIT GENOME TEST • Was recently highlighted in an article by Hume JH, et al, published in the peer-reviewed journal PrenatalDiagnosis. • MaterniT GENOME test will be presented at the 19th  International Conference on Prenatal Diagnosis and Treatment • The MaterniT GENOME test will be available to physicians laterthis quarter.
  • 13.
    SEQUENOMLABORATORIES ANNOUNCES LAUNCHOF MATERNITGENOME TEST President and Chief Executive Officerof Sequenom. •"As pioneers and innovators in noninvasive prenatal testing, we believe MaterniT GENOME represents a safe, cost effective and meaningful breakthrough in NIPT, supporting physicians in providing superior prenatal care fortheirpatients."
  • 14.
    STUDENT OBSERVATION •I thinkthis new release will be a positive thing because it is a safe way to study the baby before birth and find defects in their genome and thus find a way to improve their development
  • 15.
    MEDICAL UTILITY These studieshave great medical importance as both seek less invasive possible way to find anomalies in the fetus.
  • 16.
    MEDICAL UTILITY •The firstnews opens a new field of research into changes in the mother's pregnancy and her child 's genome .
  • 17.
    MEDICAL UTILITY •And thesecond increased the most reliable diagnostic findings and the baby before birth
  • 18.
    MEDICAL UTILITY Both studieswill be useful to find treatments to Improve Quality of Life to the baby and the mother
  • 19.
    BIBLIOGRAFIA Secuenom,inc (July 13,2015). Certain abnormal prenatal testing results and subsequent diagnosis of maternal cancer. New Medical. Retrieved July 19,2015 from www.news-medical.net/news/20150713/Sequenom-Laboratories-announces-launch-of-MaterniT   The JAMA Network Journals(July 13, 2015). Certain abnormal prenatal testing results and subsequent diagnosis of maternal cancer. Retievered July 19,2015 from www.sciencedaily.com/releases/2015/07/150713172229.htm   MARTINEZ SÁNCHEZ, Lina María. Biología molecular. 2. ed. Medellín: UPB. Fac. de Medicina, 2006. 208 p.   NCHPEG, The Jakson Laboratory.Non-Invasive Prenatal Testing Factsheet. Retrivered july 26, 2015 from www.nchpeg.org/index.php? option=com_content&view=article&id=384&Itemid=255    
  • 20.